Patents by Inventor Toralf Zarnt

Toralf Zarnt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11099180
    Abstract: The disclosure concerns a method and kits for measurement of an analyte in a microparticle-based analyte-specific binding assay. In the assay, the microparticles are coated with the first partner of a binding pair, mixing the coated microparticles and at least two analyte-specific binding agents, each conjugated to the second partner of the binding pair, and a sample suspected of containing the analyte. The second partner of the binding pair is bound to each of the analyte-specific binding agents via a linker comprising from 12 to 30 ethylene glycol units (PEG 12 to 30), thereby binding the analyte via the conjugated analyte-specific binding agents to the coated microparticles. The method also entails separating the microparticles having the analyte bound via the binding pair and the analyte-specific binding agent from the mixture and measuring the analyte bound to the microparticles.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 24, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ralf Bollhagen, Barbara Upmeier, Werner Naser, Toralf Zarnt
  • Patent number: 11078241
    Abstract: The disclosure relates to a multi-epitope fusion protein as well as to its use as calibrator and/or control in an in vitro diagnostics immunoassay for detecting HCV core antigen. The multi-epitope fusion protein has two to six different non-overlapping linear peptides present in the amino acid sequence of hepatitis C virus (HCV) core protein, wherein each of the peptides is separated from the other peptides by a spacer consisting of a non-HCV amino acid sequence and having a chaperone amino acid sequence. No further HCV specific amino acid sequences are present in the polypeptide. A further aspect relates to a reagent kit for detecting HCV core antigen containing said multi-epitope fusion protein as calibrator or control or both.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 3, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Upmeier, Ralf Bollhagen, Toralf Zarnt
  • Publication number: 20200400654
    Abstract: The present invention relates to a method for determining an analyte in a sample, comprising a) contacting said sample with at least a first and a second detector compound; b) determining the amount of complexes comprising at least one detector compound; and, c) determining said analyte in a sample based on the result of step b), wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical.
    Type: Application
    Filed: September 8, 2020
    Publication date: December 24, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Johannes Polz, Thomas Mock, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20200148726
    Abstract: The disclosure relates to a multi-epitope fusion protein as well as to its use as calibrator and/or control in an in vitro diagnostics immunoassay for detecting HCV core antigen. The multi-epitope fusion protein has two to six different non-overlapping linear peptides present in the amino acid sequence of hepatitis C virus (HCV) core protein, wherein each of the peptides is separated from the other peptides by a spacer consisting of a non-HCV amino acid sequence and having a chaperone amino acid sequence. No further HCV specific amino acid sequences are present in the polypeptide. A further aspect relates to a reagent kit for detecting HCV core antigen containing said multi-epitope fusion protein as calibrator or control or both.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 14, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Upmeier, Ralf Bollhagen, Toralf Zarnt
  • Publication number: 20190346432
    Abstract: The disclosure concerns a method and kits for measurement of an analyte in a microparticle-based analyte-specific binding assay. In the assay, the microparticles are coated with the first partner of a binding pair, mixing the coated microparticles and at least two analyte-specific binding agents, each conjugated to the second partner of the binding pair, and a sample suspected of containing the analyte. The second partner of the binding pair is bound to each of the analyte-specific binding agents via a linker comprising from 12 to 30 ethylene glycol units (PEG 12 to 30), thereby binding the analyte via the conjugated analyte-specific binding agents to the coated microparticles. The method also entails separating the microparticles having the analyte bound via the binding pair and the analyte-specific binding agent from the mixture and measuring the analyte bound to the microparticles.
    Type: Application
    Filed: August 1, 2019
    Publication date: November 14, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ralf Bollhagen, Barbara Upmeier, Werner Naser, Toralf Zarnt
  • Publication number: 20190086413
    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject with the steps of (a) contacting the sample with a surfactant comprising a cationic detergent; (b) contacting the sample with a binding compound; and (c) detecting a core polypeptide of the HCV in the sample; wherein step a) is immediately followed by step b). The present disclosure further relates to a method for pre-processing a sample from a subject for detection of an HCV core polypeptide, involving (a) contacting the sample with a surfactant comprising a cationic detergent and, optionally, with an agent inducing a pH shift, immediately followed by (b) contacting the sample with a binding compound. Moreover, the present disclosure further relates to uses, devices, and analytical systems related to aforesaid methods.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Upmeier, Toralf Zarnt, Manfred Ginter, Ralf Bollhagen
  • Publication number: 20190086412
    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ralf Bollhagen, Barbara Upmeier, Toralf Zarnt, Peter Muench, Manfred Ginter
  • Patent number: 10228370
    Abstract: The invention concerns variants of JL7 antigens that are suitable for detecting antibodies against Trypanosoma cruzi (causing Chagas disease) in an isolated biological sample. These antigens comprise a JL7 specific amino acid sequence, said JL7 specific sequence consisting of two copies of SEQ ID NO. 2, wherein each of said two copies has an amino acid identity of at least 90% to SEQ ID NO.2 and wherein no further Trypanosoma cruzi specific amino acid sequences are present in said polypeptide. The invention also concerns a composition of polypeptides useful for the detection of antibodies against Trypanosoma cruzi that comprises the above characterized JL7 antigen along with at least one of T. cruzi polypeptides 1F8, Cruzipain, KMP-11 and PAR-2. Moreover, it relates to a method for producing JL7 antigen as well as to diagnostic methods for detecting T. cruzi antibodies using the JL7 polypeptide.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: March 12, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Roessler, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20180348211
    Abstract: Disclosed is an immunoassay method for detecting an analyte such as an antigen or an antibody in an isolated sample suspected to contain the analyte by incubating the sample with a plurality of binding partners, one of which carries a detectable label, wherein a label-specific binding partner is added that does not carry a label but binds to the detectable label. The method is applicable for a large variety of analytes and has proven particularly useful for analyte antibodies of the IgG and IgM class present in samples due to infections by pathogens. Also disclosed is a reagent kit useful for the method comprising at least two analyte-specific binding partners one of which carries a detectable label and a label-specific binding partner that binds to said detectable label but itself does not carry a detectable label.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 6, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Upmeier, Toralf Zarnt, Dieter Roessler, Johannes Polz
  • Patent number: 10094828
    Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 9, 2018
    Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20180172680
    Abstract: Disclosed is a method for measurement of an analyte in a microparticle-based analyte-specific binding assay, wherein the microparticles are coated with the first partner of a binding pair, the method involving mixing the coated microparticles, an analyte-specific binding agent conjugated to the second partner of the binding pair, and a sample suspected of containing or containing the analyte, wherein the second partner of the binding pair is bound to the analyte-specific binding agent via a linker having from 12 to 30 ethylene glycol units (PEG 12 to 30), thereby binding the analyte via the conjugated analyte-specific binding agent to the coated microparticles, separating the microparticles having the analyte bound via the binding pair and the analyte-specific binding agent from the mixture and measuring the analyte bound to the microparticles.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Toralf Zarnt, Dieter Heindl, Alfons Nichtl, Frank Sicherl-Birk
  • Publication number: 20180128825
    Abstract: The present invention relates to a method for determining an analyte in a sample suspected to comprise said analyte, comprising a) contacting with said sample at least a first and a second capture compound for said analyte, wherein said first and second capture compounds are non-identical capture compounds, and wherein said capture compounds compete in binding to said analyte; b) contacting said capture compounds contacted with said sample with a specifier, wherein said specifier competes in binding to said capture compounds with said analyte; c) determining the amount of complexes comprising said specifier and a capture compound; and d) determining said analyte in a sample based on the result of step c).
    Type: Application
    Filed: June 13, 2017
    Publication date: May 10, 2018
    Inventors: Barbara Upmeier, Toralf Zarnt, Johannes Polz
  • Publication number: 20170248598
    Abstract: The invention concerns variants of JL7 antigens that are suitable for detecting antibodies against Trypanosoma cruzi (causing Chagas disease) in an isolated biological sample. These antigens comprise a JL7 specific amino acid sequence, said JL7 specific sequence consisting of two copies of SEQ ID NO. 2, wherein each of said two copies has an amino acid identity of at least 90% to SEQ ID NO.2 and wherein no further Trypanosoma cruzi specific amino acid sequences are present in said polypeptide. The invention also concerns a composition of polypeptides useful for the detection of antibodies against Trypanosoma cruzi that comprises the above characterized JL7 antigen along with at least one of T. cruzi polypeptides 1F8, Cruzipain, KMP-11 and PAR-2. Moreover, it relates to a method for producing JL7 antigen as well as to diagnostic methods for detecting T. cruzi antibodies using the JL7 polypeptide.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 31, 2017
    Inventors: Dieter Roessler, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20170248597
    Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 31, 2017
    Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20160145281
    Abstract: Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in the electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: September 28, 2015
    Publication date: May 26, 2016
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
  • Patent number: 8835637
    Abstract: Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in the electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: September 16, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
  • Patent number: 8772486
    Abstract: Novel iridium-based Ir (III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: July 8, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
  • Publication number: 20130323719
    Abstract: Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in the electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 5, 2013
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
  • Publication number: 20130323857
    Abstract: Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 5, 2013
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Eloisa Lopez-Calle, Toralf Zarnt
  • Patent number: 8551696
    Abstract: The invention relates to soluble rubella E1 antigens and variants of these antigens. The antigens contain amino acids 201 to 432 or 169 to 432 and are lacking amino acids 453 to 481 as well as at least the amino acids 143 to 164. They further contain a region spanning two disulfide-bridges. The invention also relates to a recombinant DNA molecule encoding the rubella E1 antigens, the expression of rubella E1 antigens as chaperone fusion proteins and their use in a method of detecting antibodies against rubella in a sample.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: October 8, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Christian Scholz, Ralf Bollhagen, Alfred Engel, Elke Faatz, Peter Schaarschmidt, Barbara Upmeier, Toralf Zarnt